NYC Agar Base

M1348

Intended Use:

Recommended for selective isolation of Gonococci.

Composition**

Ingredients	g / L
Proteose peptone	15.000
Corn starch	1.000
Dextrose (Glucose)	5.000
Sodium chloride	5.000
Dipotassium hydrogen phosphate	4.000
Potassium dihydrogen phosphate	1.000
Agar	20.000
Final pH (at 25°C)	7.4±0.2

**Formula adjusted, standardized to suit performance parameters

Directions

Suspend 25.50 grams in 320 ml purified/distilled water. Heat to boiling to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Avoid overheating. Cool to 45-50°C and add aseptically 100 ml of sedimented horse blood cells and 60 ml of citrated horse plasma along with rehydrated contents of one vial of NYC Supplement (FD150) and one vial of Yeast Autolysate Supplement (FD027). Mix well and pour into sterile Petri plates.

Principle And Interpretation

NYC Agar Base was originally developed by Fauer, Weisburd and Wilson (1-3) at the New York City Department of Health for selective isolation of pathogenic *Neisseria* species from clinical specimens. It consists of primarily a peptone-corn starch-agar-base buffered with phosphates and supplemented with horse plasma, horse haemoglobin, dextrose, yeast autolysate and antibiotics (1,2). This medium is superior to other media generally employed for the isolation of *Neisseria* species (1,4,5). The transparent nature of the medium helps in studying the colonial types (6).

Proteose peptone, horse plasma, haemoglobin provide nutrients for the growth of *N. gonorrhoeae* and *N. meningitidis*. Phosphate buffers the medium. The selective supplement added contains the antibiotics vancomycin, colistin, nystatin and trimethoprim, to suppress the accompanying flora. Vancomycin is inhibitory for gram-positive bacteria. Colistin inhibits gram-negative bacteria, including *Pseudomonas* species, while *Proteus* is inhibited by trimethoprim (7). The combination of trimethoprim and colistin acts synergistically against gram-negative bacilli (8). Starch neutralizes the toxic metabolites produced by *Neisseria*. The yeast autolysate supplement fulfils the CO_2 requirements needed to enhance *Neisseria* growth. Yeast contains oxaloacetic acid which is metabolized by gonococci to produce sufficient CO_2 for growth of capnophilic gonococci (9). Also, presence of yeast autolysate reduces the lag phase of growth of *Neisseria*, thus enhancing both size and number of colonies. The specimen can be directly streaked on the medium to obtain maximum isolation.

Type of specimen

Clinical samples : Throat swabs, vaginal secretions, rectum and urethra swabs

Specimen Collection and Handling:

For clinical samples follow appropriate techniques for handling specimens as per established guidelines (10,11).
After use, contaminated materials must be sterilized by autoclaving before discarding.

Warning and Precautions :

In Vitro diagnostic Use only. For professional use only. Read the label before opening the container. Wear protective gloves/protective clothing/eye protection/ face protection. Follow good microbiological lab practices while handling specimens and culture. Standard precautions as per established guidelines should be followed while handling clinical specimens. Safety guidelines may be referred in individual safety data sheets.

Limitations :

1.Due to nutritional variations and fastidious nature of organisms certain strains may show poor growth.

Performance and Evaluation

Performance of the medium is expected when used as per the direction on the label within expiry period when stored at the recommended temperature.

Quality Control

Appearance

Cream to yellow homogeneous free flowing powder

Gelling

Firm, comparable with 2.0% agar gel.

Colour and Clarity of Prepared medium

Yellow coloured clear to slightly opalescent gel forms in Petri plates

Reaction

Reaction of 5.1% w/v aqueous solution at 25°C. pH : 7.4±0.2

pH

7.20-7.60

Cultural Response

Cultural characteristics observed after in presence of 5-10% CO_2 and 70% humidity with added sedimented horse blood cells and citrated horse plasma along with rehydrated contents of 1 vial of NYC Supplement (FD150) and 1 vial of Yeast Autolysate Supplement (FD027), after an incubation at 35-37°C for 40-48 hours.

Organism	Inoculum (CFU)	Growth	Recovery
Haemophilus influenzae ATCC 19418	50-100	good-luxuriant	>=50%
Neisseria gonorrhoea ATCC 19424	50-100	good-luxuriant	>=50%
Neisseria meningitidis ATCC 13090	50-100	good-luxuriant	>=50%
Streptococcus pneumoniae ATCC 6303	50-100	good-luxuriant	>=50%
Streptococcus pyogenes ATCC 19615	50-100	good-luxuriant	>=50%
Pseudomonas aeruginosa ATCC 27853 (00025*)	50-100	none-poor	<=10%
Proteus mirabilis ATCC 13883	50-100	none-poor	<=10%

Key : *Corresponding WDCM numbers.

Storage and Shelf Life

Store between 10-30°C in a tightly closed container and the prepared medium at 2-8°C. Use before expiry date on the label. On opening, product should be properly stored dry, after tightly capping the bottle inorder to prevent lump formation due to the hygroscopic nature of the product. Improper storage of the product may lead to lump formation. Store in dry ventilated area protected from extremes of temperature and sources of ignition Seal the container tightly after use. Product performance is best if used within stated expiry period.

Disposal

User must ensure safe disposal by autoclaving and/or incineration of used or unusable preparations of this product. Follow established laboratory procedures in disposing of infectious materials and material that comes into contact with clinical sample must be decontaminated and disposed of in accordance with current laboratory techniques (10,11).

Reference

1. Fauer, Weisburd, Wilson and May, 1973, Health Lab. Sci., 10: 44.
2. Fauer, Weisburd and Wilson, 1973, Health Lab. Sci., 10: 55.
3. Fauer Y. C., Weisburd M. H. and Wilson M. E., 1973, Health Lab Sci., 10(2), 61.

4. Granato, Schneible-Smith and Weiner, 1981, J. Clin. Microbiol.13:963.
5. Griffin P. J. and Reider S. V., 1957, J. Biol. Med., 29, 613.
6. MacFaddin J. F., 1985, Media for Isolation-Cultivation-Identification-Maintenance of Medical Bacteria, Vol. 1, Williams and Wilkins, Baltimore
7. Murray P. R., Baron J. H., Pfaller M. A., Tenover F. C. and Yolken R. H. (Eds.), 1999, Manual of Clinical Microbiology,7th Ed., American Society for Microbiology, Washington, D.C.
8. Simmons N. A., 1970, J. Clin. Pathol., 23, 757.
9. Lawton and Koch, 1982, J. Clin. Microbiol., 20: 905.
10. Isenberg, H.D. Clinical Microbiology Procedures Handbook 2nd Edition.
11. Jorgensen, J.H., Pfaller, M.A., Carroll, K.C., Funke, G., Landry, M.L., Richter, S.S and Warnock., D.W. (2015) Manual of Clinical Microbiology, 11th Edition. Vol. 1.

Revision : 03/2024

HiMedia Laboratories Pvt. Limited,
Plot No.C-40, Road No.21Y,
MIDC, Wagle Industrial Area,
Thane (W) -400604, MS, India

IVD ***In vitro* diagnostic medical device**



Storage temperature

EC REP CEpartner4U, Esdoornlaan 13,
3951DB Maarn, NL
www.cepartner4u.eu

CE Marking

Do not use if package is damaged

Disclaimer :

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related HiMedia™ publications. The information contained in this publication is based on our research and development work and is to the best of our knowledge true and accurate. HiMedia™ Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory,diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.